Open/close main nav Menu Menu MYMETRO Collapse + - ER/URGENT CARE
MyMetro
  • Emergency & Urgent Care

    Is this an Emergency?

    In an emergency, seconds count. If you are alarmed by unusually severe symptoms, seek immediate care. Please call 911 if you feel your condition is life threatening. If a poison is involved, please call Grand Rapids Poison Control Center at (800) 222-1222.

    When to go to the Emergency Room When to go to Urgent Care
  • Hospital ER
    NOW OPEN

    Emergency Room Hours:
    24 hours a day, 7 days a week

    • Directions to the ER

      5900 BYRON CENTER AVE SW

      WYOMING, MI

      (616) 252-7200

      map
  • Urgent Care

    Urgent Care Hours:
    Open 9 am - 9 pm, 7 days a week

    • Directions to Urgent Care

      4055 CASCADE RD SE

      GRAND RAPIDS, MI

      (616) 252-4010

      map

Metro Health Physician is Among First in United States to Use New Medical Device to Treat PAD

Metro Health cardiovascular specialist Dr. Jihad Mustapha is one of the first physicians in the United States to use a new medical device to treat peripheral arterial disease.

The nationally recognized physician dedicated to amputation prevention successfully debuted the new Lutonix® 035 Drug Coated Balloon Percutaneous Transluminal Angioplasty Catheter in two procedures yesterday at Metro Health. Developed by C.R. Bard, Inc., the new device allows physicians to re-open arteries in the thigh and knee when narrowed as a result of peripheral artery disease.

Mustapha successfully used the new device to clear blockages in the limbs of two Metro Health patients, who traveled from Florida and California for the procedures.

This is the fourth new medical device to debut at Metro Health to treat PAD. Over the past two years, Mustapha and other cardiovascular physicians have been selected to be among the first in the United States – and on at least one occasion, the world – to use breakthrough technology, successfully treating hundreds of patients and preventing amputation of their feet or legs.

In June, Mustapha traveled to Washington, D.C. to testify on the effectiveness of the new device, helping to secure its FDA approval. Lutonix 035 DCB uses the drug paclitaxel, which has previously been used as a cancer chemotherapy drug, to prevent blockages from recurring in arteries after balloon angioplasty. Prior to using the Lutonix 035 DCB, Mustapha used a traditional angioplasty balloon without a drug coating. He then used the new device to fully open the artery and apply the drug to the artery wall.

PAD is a common progressive circulatory problem in which narrowed arteries block the blood flow to arms and legs, causing numbness, leg pain, tissue damage and leading to amputation.

The hospital has developed a nationally recognized specialty in the treatment of PAD and amputation prevention, last year treating scores of patients from around Michigan, across the country and throughout the world. Led by Mustapha, Metro Heart & Vascular physicians utilize leading-edge technology, such as the new Lutonix device, to clear blockages and restore circulation in even the most challenging of cases.

“The new Lutonix drug coated balloon is a game changer in treating patients who suffer from PAD and its most advanced state which is critical limb ischemia, or CLI,” said Mustapha. “Because PAD and CLI are progressive, patients often face recurring interventions. Simply put, once we re-open a vessel, the body can overcompensate for the repair by sending new tissue to close the vessel again.

“Research shows that vessels treated with the Lutonix DCB remain open significantly longer, helping patients avoid the costs, inconvenience and discomfort of repeated procedures. Over time, the device will allow us to treat more patients, thus helping them remain active and engaged with their lives and families.”

As many as 12 million Americans, most over the age of 65, suffer from PAD, which is caused by the accumulation of plaque in peripheral arteries reducing blood flow. Left untreated, PAD can lead to severe pain, immobility, non-healing wounds and eventually amputation.

Patients at high risk include those who are obese or have diabetes, heart disease or other circulatory issues. Smokers are also at a higher risk, as are African Americans and Native Americans.

For more information on Metro Heart & Vascular, visit https://metrohealth.net/medical-services/heart-vascular-services/.

For more information on the Lutonix DCB, visit http://www.bardpv.com/_vascular/product.php?p=254.

About Metro Health

An award-winning leader in community healthcare, Metro Health serves more than 250,000 patients annually from across West Michigan – and beyond.  In addition to its 208-bed hospital, which provides a comprehensive suite of inpatient and outpatient healthcare services, Metro Health has a growing number neighborhood outpatient centers and offices throughout West Michigan, as well as a community clinic for the underserved and a student health clinic on the campus of Grand Valley State University.  With more than 500 physicians on staff, Metro Health provides a growing number of specialty health services, including cancer treatment, heart and vascular, neurology, pulmonology and others.  Many are members of the Metro Health Medical Group.  The hospital is committed to promoting health and wellness through the work of the Metro Health Hospital Foundation, Live Healthy community outreach classes and educational programs and more.  Visit us www.metrohealth.net, follow us on Twitter @MetroHealthGr and like us on Facebook/MetroHealth.

Subscribe

Social Media

Related Content

People

Jihad A. Mustapha, MD

Services

Heart & Vascular

joseph.weller@metrogr.org